Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis.


Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
21 02 2020
Historique:
received: 24 07 2019
accepted: 26 11 2019
pubmed: 18 12 2019
medline: 15 12 2020
entrez: 18 12 2019
Statut: epublish

Résumé

Durlobactam (DUR; ETX2514) is a novel β-lactamase inhibitor with broad-spectrum activity against Ambler class A, C, and D β-lactamases. Durlobactam restores the

Identifiants

pubmed: 31843995
pii: AAC.01506-19
doi: 10.1128/AAC.01506-19
pmc: PMC7038258
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Cilastatin, Imipenem Drug Combination 92309-29-0
Sulbactam S4TF6I2330

Banques de données

ClinicalTrials.gov
['NCT03445195']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2020 Sagan et al.

Références

Crit Care. 2016 Jul 11;20(1):221
pubmed: 27417949
Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S34-S46
pubmed: 30895213
Nat Microbiol. 2017 Jun 30;2:17104
pubmed: 28665414
Antimicrob Agents Chemother. 2018 Jan 25;62(2):
pubmed: 29133555
Crit Care Med. 2015 Jun;43(6):1194-204
pubmed: 25793437
Emerg Infect Dis. 2018 Apr;24(4):727-734
pubmed: 29553339
Lancet Infect Dis. 2018 Apr;18(4):391-400
pubmed: 29456043
ACS Infect Dis. 2017 Nov 10;3(11):833-844
pubmed: 28835096
Crit Care Med. 2015 Jun;43(6):1332-4
pubmed: 25978159
Clin Microbiol Infect. 2014 May;20(5):416-23
pubmed: 24131374
Open Forum Infect Dis. 2017 Aug 16;4(3):ofx176
pubmed: 29026867
Antimicrob Agents Chemother. 2019 Aug 23;63(9):
pubmed: 31307978
mBio. 2019 Mar 12;10(2):
pubmed: 30862744
Am J Infect Control. 2019 Sep;47(9):1140-1145
pubmed: 31003750
Curr Opin Crit Care. 2016 Oct;22(5):491-9
pubmed: 27552304
Semin Respir Crit Care Med. 2017 Jun;38(3):311-325
pubmed: 28578555
Antimicrob Agents Chemother. 2018 Oct 24;62(11):
pubmed: 30126953
Infect Control Hosp Epidemiol. 2013 Jan;34(1):1-14
pubmed: 23221186
Clin Microbiol Rev. 2017 Jan;30(1):409-447
pubmed: 27974412
J Hosp Med. 2016 Jan;11(1):21-6
pubmed: 26353076

Auteurs

Olexiy Sagan (O)

Regional Clinical Hospital of Zaporizhzhia, Zaporizhzhia, Ukraine.

Ruslan Yakubsevitch (R)

Grodno Regional Clinical Hospital, Hrodna, Belarus.

Krassimir Yanev (K)

Clinic of Urology, Sofia, Bulgaria.

Roman Fomkin (R)

Saratov State Medical University, Saratov, Russia.

Emily Stone (E)

Spero Therapeutics, Cambridge, Massachusetts, USA.

Daniel Hines (D)

Entasis Therapeutics, Inc., Waltham, Massachusetts, USA.

John O'Donnell (J)

Entasis Therapeutics, Inc., Waltham, Massachusetts, USA.

Alita Miller (A)

Entasis Therapeutics, Inc., Waltham, Massachusetts, USA.

Robin Isaacs (R)

Entasis Therapeutics, Inc., Waltham, Massachusetts, USA.

Subasree Srinivasan (S)

Entasis Therapeutics, Inc., Waltham, Massachusetts, USA suba.srinivasan@entasistx.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH